Key Points
- Director Robert Bessler sold 119,942 shares of LifeStance Health Group on December 19 at an average price of $7.04 for $844,391.68, lowering his holding by 8.34% to 1,318,983 shares; the sale was disclosed in an SEC filing.
- Bessler made multiple additional December sales (Dec. 12, 15, 18 and 22) totaling about $701,872, bringing his combined December dispositions to roughly $1.55 million.
- LFST trades around $7.06 with a 1‑year range of $3.74–$8.30 and a $2.75B market cap, and analysts maintain a consensus "Moderate Buy" with a $8.83 price target (several firms have raised targets to $10).
LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) Director Robert Bessler sold 119,942 shares of the firm's stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $7.04, for a total transaction of $844,391.68. Following the completion of the transaction, the director directly owned 1,318,983 shares in the company, valued at $9,285,640.32. This represents a 8.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Robert Bessler also recently made the following trade(s):
- On Monday, December 22nd, Robert Bessler sold 1,701 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.04, for a total value of $11,975.04.
- On Thursday, December 18th, Robert Bessler sold 6,442 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.00, for a total value of $45,094.00.
- On Monday, December 15th, Robert Bessler sold 12,371 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.00, for a total value of $86,597.00.
- On Friday, December 12th, Robert Bessler sold 79,630 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.01, for a total value of $558,206.30.
LifeStance Health Group Stock Performance
LFST stock opened at $7.06 on Wednesday. LifeStance Health Group, Inc. has a 1-year low of $3.74 and a 1-year high of $8.30. The business has a 50-day moving average price of $6.07 and a 200 day moving average price of $5.38. The company has a market capitalization of $2.75 billion, a P/E ratio of -235.33 and a beta of 1.13. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.58 and a quick ratio of 1.58.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $0.03. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The business had revenue of $363.81 million for the quarter, compared to the consensus estimate of $355.06 million. During the same quarter last year, the firm posted ($0.02) EPS. The company's revenue for the quarter was up 16.3% on a year-over-year basis. As a group, equities research analysts forecast that LifeStance Health Group, Inc. will post -0.18 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on the stock. UBS Group boosted their price objective on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a "buy" rating in a research note on Friday, November 7th. BTIG Research boosted their price target on LifeStance Health Group from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Friday, December 12th. BMO Capital Markets assumed coverage on LifeStance Health Group in a research note on Thursday, November 13th. They set an "outperform" rating and a $8.00 price objective for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of LifeStance Health Group in a research note on Monday. Finally, Zacks Research downgraded shares of LifeStance Health Group from a "strong-buy" rating to a "hold" rating in a report on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, LifeStance Health Group presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.83.
Get Our Latest Stock Analysis on LifeStance Health Group
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in LFST. Invesco Ltd. boosted its holdings in LifeStance Health Group by 1.4% in the first quarter. Invesco Ltd. now owns 164,384 shares of the company's stock worth $1,095,000 after acquiring an additional 2,238 shares in the last quarter. Vident Advisory LLC raised its position in shares of LifeStance Health Group by 12.7% in the 2nd quarter. Vident Advisory LLC now owns 21,732 shares of the company's stock valued at $112,000 after purchasing an additional 2,447 shares during the last quarter. State of Wyoming boosted its stake in LifeStance Health Group by 3.8% in the 3rd quarter. State of Wyoming now owns 89,927 shares of the company's stock worth $495,000 after purchasing an additional 3,298 shares in the last quarter. Legal & General Group Plc grew its position in LifeStance Health Group by 2.4% during the 2nd quarter. Legal & General Group Plc now owns 144,263 shares of the company's stock worth $746,000 after purchasing an additional 3,331 shares during the last quarter. Finally, Polar Capital Holdings Plc increased its stake in LifeStance Health Group by 19.3% during the 3rd quarter. Polar Capital Holdings Plc now owns 21,775 shares of the company's stock valued at $120,000 after purchasing an additional 3,525 shares in the last quarter. 85.50% of the stock is owned by institutional investors and hedge funds.
LifeStance Health Group Company Profile
(
Get Free Report)
LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.
The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
